3.5.2.B2	(+)-gamma-lactamase	drug development	application of the enzyme in antiviral drug synthesis. The enzyme catalyzes the specific hydrolysis of (+)-gamma-lactam out of the racemic gamma-lactam (2-azabicyclo[2.2.1]hept-5-en-3-one) to leave optically pure (-)-gamma-lactam, which is the key building block of antiviral drugs such as carbovir and abacavir	
3.5.2.B2	(+)-gamma-lactamase	drug development	the enzyme can be a promising candidate of biocatalyst for industrial applications of highly valuable chiral pharmaceutical chemicals	
3.5.2.B2	(+)-gamma-lactamase	drug development	the enzyme is an ideal catalyst for the preparation of carbocyclic nucleosides of pharmaceutical interest. IT can be used in a scalable bioprocess and is an efficient, economical, and environmentally route for producing optically pure (-)-gamma-lactam	
3.5.2.B2	(+)-gamma-lactamase	drug development	the use of gamma-lactamase as a biocatalyst offers an attractive and environmentally friendly approach for the synthesis of a broad range of carbocyclic nucleoside drugs. The enzyme can be used for enzymatic kinetic resolution of racemic Vince lactam (2-azabicyclo[2.2.1]hept-5-en-3-one) in the industry. Optically pure enantiomers and their hydrolytic products are widely employed as key chemical intermediates for developing a wide range of carbocyclic nucleoside medicines, including US FDA-approved drugs peramivir and abacavir	
1.14.14.167	(13S,14R)-13-O-acetyl-1-hydroxy-N-methylcanadine 8-hydroxylase	drug development	reconstitute of the noscapine gene cluster in Saccharomyces cerevisiae to achieve the microbial production of noscapine and related pathway intermediates	
2.5.1.10	(2E,6E)-farnesyl diphosphate synthase	drug development	the discovery of new binding sites and non-bisphosphonate binders is a critical step towards the investigation of farnesyl pyrophosphate synthase as a drug target for human African trypanosomiasis and opens up the possibility of a fragment-to-lead optimisation program	
2.5.1.92	(2Z,6Z)-farnesyl diphosphate synthase	drug development	the enzyme possibly represents an attractive drug target for the development of selective inhibitors aiming the erythrocytic stages of Plasmodium falciparum and development of more potent bisphosphonate-based inhibitors selectivity targeting this key point of the plasmodial isoprenoid metabolism	
2.3.2.24	(E3-independent) E2 ubiquitin-conjugating enzyme	drug development	E2 ubiquitin-conjugating enzymes might be potential drug targets, potential strategies for drug discovery targeting UBE2O, overview	
4.2.3.20	(R)-limonene synthase	drug development	D-limonene is effective in cancer prevention in animal cancer models, some clinical applications have been performed	
1.1.3.15	(S)-2-hydroxy-acid oxidase	drug development	in humans the enzyme is a potential drug target for treatment of primary hyperoxaluria, a genetic disorder where overproduction of oxalate results in the formation of kidney stones	
1.1.3.15	(S)-2-hydroxy-acid oxidase	drug development	isozyme Hao2 is a target for drug development in high blood pressure	
4.1.2.47	(S)-hydroxynitrile lyase	drug development	industrial processes	
2.4.1.18	1,4-alpha-glucan branching enzyme	drug development	small molecules with diverse scaffolds but similar three-dimensional structures show a similar biological effect. Deriving scaffolds from docking and similarity search is a successful design strategy for difficult targets	
4.1.3.36	1,4-dihydroxy-2-naphthoyl-CoA synthase	drug development	the enzyme is a target for development of antibacterial agents	
2.3.1.67	1-alkylglycerophosphocholine O-acetyltransferase	drug development	identification of LPCAT2-specific inhibitors in order to ameliorate PAF-related inflammatory diseases, fluorescence-based high-throughput library screening	
1.1.1.267	1-deoxy-D-xylulose-5-phosphate reductoisomerase	drug development	the enzyme is a potential target for antimalarial drug development and chemotherapy	
1.1.1.267	1-deoxy-D-xylulose-5-phosphate reductoisomerase	drug development	the enzyme is a target for antibacterial agents and inhibitor design	
1.1.1.267	1-deoxy-D-xylulose-5-phosphate reductoisomerase	drug development	the enzyme is an excellent drug target in a number of pathogenic organisms	
1.1.1.267	1-deoxy-D-xylulose-5-phosphate reductoisomerase	drug development	Escherichia coli Dxr represents a valuable model enzyme for the screening for new antimalarial compounds, since work with the Plasmodium falciparum Dxr is associated with considerably high effort due to the instability of this enzyme and the low yield of the available recombinant expression system, no major differences in the IC50 between Escherichia coli Dxr and Plasmodium falciparum Dxr	
1.1.1.267	1-deoxy-D-xylulose-5-phosphate reductoisomerase	drug development	1-deoxy-D-xylulose-5-phosphate reductoisomerase in the nonmevalonate isoprene biosynthesis pathway is a target for developing antimalarial drugs	
1.1.1.267	1-deoxy-D-xylulose-5-phosphate reductoisomerase	drug development	because the enzyme is absent in humans, DXR is a target for drug discovery	
1.1.1.267	1-deoxy-D-xylulose-5-phosphate reductoisomerase	drug development	the enzyme is a target for the design of antimalarial drugs	
1.1.1.267	1-deoxy-D-xylulose-5-phosphate reductoisomerase	drug development	enzyme DXR is a validated antimicrobial target	
1.1.1.267	1-deoxy-D-xylulose-5-phosphate reductoisomerase	drug development	enzyme DXR is an antimicrobial target	
1.1.1.267	1-deoxy-D-xylulose-5-phosphate reductoisomerase	drug development	the enzyme from Escherichia coli is a valuable target for the development of antimicrobial compounds	
1.1.1.267	1-deoxy-D-xylulose-5-phosphate reductoisomerase	drug development	the enzyme from Mycobacterium smegmatis is a valuable target for the development of antimicrobial compounds	
1.1.1.267	1-deoxy-D-xylulose-5-phosphate reductoisomerase	drug development	the methyl erythritol phosphate (MEP) pathway represents an attractive series of targets for antibiotic design, considering each enzyme of the pathway is both essential and has no human homologues, including enzymes DXP reductoisomerase (IspC) and MEP cytidylyltransferase (IspD)	
2.2.1.7	1-deoxy-D-xylulose-5-phosphate synthase	drug development	DXS is an attractive target for the development of antibiotics, antimalarials, and herbicides	
2.7.1.67	1-phosphatidylinositol 4-kinase	drug development	type II phosphatidylinositol 4-kinases are promising targets for therapeutic intervention against viral infections, detailed overview	
2.7.1.150	1-phosphatidylinositol-3-phosphate 5-kinase	drug development	potential for targeting this kinase in developing small-molecule antivirals against SARS-CoV-2. The infection is fully blocked by bafilomycin A1, which inhibits the vacuolar type H+-ATPase (V-ATPase) acidification activity. Apilimod and vacuolin-1 prevent cytoplasmic entry of VSV-MeGFP-ZEBOV (from Zaire ebolavirus VSV-ZEBOV)	
2.7.1.150	1-phosphatidylinositol-3-phosphate 5-kinase	drug development	the enzyme is a potential target for developing small-molecule antivirals against SARS-CoV-2	
1.1.1.146	11beta-hydroxysteroid dehydrogenase	drug development	isozyme 11beta-HSD1 is a target in treatment of metabolic diseases such as diabetes mellitus type 2 or obesity	
1.1.1.146	11beta-hydroxysteroid dehydrogenase	drug development	11beta-HSD1 will significantly contribute to the biotransformation of oracin in humans. The microsomal carbonyl reductase has a great potential to significantly impair the chemotherapy with the anticancer drug oracin	
1.1.1.B40	11beta-hydroxysteroid dehydrogenase (NAD+)	drug development	the enzyme is a target for inhibitor design and development	
1.1.1.141	15-hydroxyprostaglandin dehydrogenase (NAD+)	drug development	induction of 15-hydroxyprostaglandin dehydrogenase expression or utilization of 15-keto-PGE2 analogue may have therapeutic benefits for the treatment of endotoxin-associated liver inflammation/injury	
2.1.1.179	16S rRNA (guanine1405-N7)-methyltransferase	drug development	development of potent agents against 16S-RMTase producers as targets for treatment of multidrug resistant bacteria	
1.14.14.32	17alpha-hydroxyprogesterone deacetylase	drug development	regioisomeric 17beta-N-phenylpyrazolyl steroid derivatives have weak inhibitory effect on 17alpha-hydroxylase/C17,20-lyase	
1.14.14.32	17alpha-hydroxyprogesterone deacetylase	drug development	silencing CYP17 expression may be a strategy for therapy of hyperandrogenism diseases, and also sets an example for the use of RNAi technology in endocrine diseases	
1.1.1.62	17beta-estradiol 17-dehydrogenase	drug development	several 17beta-HSD isozymes are targets for drug development with importance in cancer, metabolic diseases, neurodegeneration and possibly immunity	
1.1.1.62	17beta-estradiol 17-dehydrogenase	drug development	the enzyme is considered a promising drug target against estrogen-dependent cancers	
1.1.1.62	17beta-estradiol 17-dehydrogenase	drug development	the enzyme constitutes an interesting therapeutic target for estrogen-dependent diseases	
2.3.1.22	2-acylglycerol O-acyltransferase	drug development	[acyl CoA]monoacylglycerol acyltransferase 2 (MGAT2) is of interest as a target for therapeutic treatment of diabetes, obesity and other diseases which together constitute the metabolic syndrome	
2.7.6.3	2-amino-4-hydroxy-6-hydroxymethyldihydropteridine diphosphokinase	drug development	the enzyme is a target for antibiotic development	
2.7.6.3	2-amino-4-hydroxy-6-hydroxymethyldihydropteridine diphosphokinase	drug development	the enzyme is a target for antimicrobial development	
4.6.1.12	2-C-methyl-D-erythritol 2,4-cyclodiphosphate synthase	drug development	framework for the development of IspF inhibitors to generate lead compounds of therapeutic potential against microbial pathogens	
2.7.7.60	2-C-methyl-D-erythritol 4-phosphate cytidylyltransferase	drug development	due to the absence of the pathway in mammals enzyme provides a potential target for new antibiotics	
2.7.7.60	2-C-methyl-D-erythritol 4-phosphate cytidylyltransferase	drug development	insights in structure and function of MtIspD	
2.7.7.60	2-C-methyl-D-erythritol 4-phosphate cytidylyltransferase	drug development	2-C-methyl-D-erythritol 4-phosphate cytidyltransferase, enzyme IspD, is a potential therapeutic drug target in Plasmodium vivax	
2.7.7.60	2-C-methyl-D-erythritol 4-phosphate cytidylyltransferase	drug development	IspD is a druggable target for the development of additional antimalarial agents. 1R,3S-MMV008138 shows promise as a potential scaffold for target-based antimalarial drug development	
2.7.7.60	2-C-methyl-D-erythritol 4-phosphate cytidylyltransferase	drug development	PfIspD enzyme inhibitor MMV008138 does not target the human IspD, reinforcing MMV008138 as a prototype of a distinct class of species-selective IspD-targeting antimalarial agents	
2.7.7.60	2-C-methyl-D-erythritol 4-phosphate cytidylyltransferase	drug development	the methyl erythritol phosphate (MEP) pathway, including enzyme MEP cytidylyltransferase (IspD), represents an attractive series of targets for antibiotic design, considering each enzyme of the pathway is both essential and has no human homologues	
2.3.1.230	2-heptyl-4(1H)-quinolone synthase	drug development	the enzyme PqsBC is a potential drug target	
2.3.3.13	2-isopropylmalate synthase	drug development	the enzyme is required for the proliferation of Mycobacterium tuberculosis and is also indispensable for its survival during the latent phase of infection. It is absent in humans and is widely regarded as one of the validated drug targets against Tuberculosis	
2.3.3.5	2-methylcitrate synthase	drug development	androstenedione is an important steroid medicine intermediate that is obtained via the degradation of phytosterols by mycobacteria. The production process of androstenedione is mainly the degradation of the phytosterol aliphatic side chain, which is accompanied by the production of propionyl CoA. Excessive accumulation of intracellular propionyl-CoA produces a toxic effect in mycobacteria, which restricts the improvement of production efficiency. Biotransformation at low nitrogen levels can be improved by enhancing the methylcitrate cycle with transcriptional regulators PrpR and GlnR of Mycobacterium neoaurum	
2.3.3.5	2-methylcitrate synthase	drug development	the fungi-specific 2-methylcitrate cycle is responsible for detoxifying propionyl-CoA, a toxic metabolite produced as the fungus breaks down proteins and amino acids. The enzyme responsible for this detoxification is 2-methylcitrate synthase (mcsA) and is a potential candidate for the design of new anti-fungals	
1.1.1.51	3(or 17)beta-hydroxysteroid dehydrogenase	drug development	the steroidogenic enzyme 17beta-hydroxysteroid dehydrogenase type 3 (17beta-HSD3) is a therapeutic target in the management of androgen-sensitive diseases such as prostate cancer and benign prostate hyperplasia	
4.1.99.12	3,4-dihydroxy-2-butanone-4-phosphate synthase	drug development	the enzyme is a target in antimicrobial inhibitor development, structure-based inhibitor design	
4.1.99.12	3,4-dihydroxy-2-butanone-4-phosphate synthase	drug development	the enzyme is an attractive target for antibiotics, design of mechanism-based inhibitors	
4.1.99.12	3,4-dihydroxy-2-butanone-4-phosphate synthase	drug development	the enzyme is a potential anti-infective target in the pathogenic yeast	
4.2.1.10	3-dehydroquinate dehydratase	drug development	absence of the shikimate patway from humans makes the enzymes of this pathway potential drug targets	
4.2.1.10	3-dehydroquinate dehydratase	drug development	the absence of DHQD in humans and its essentiality in many pathogenic bacteria make the enzyme a target for the development of nontoxic antimicrobials and design of type I DHQD inhibiting molecules	
4.2.1.10	3-dehydroquinate dehydratase	drug development	the enzyme is an attractive target for the development of new antimicrobials and herbicides	
4.2.3.4	3-dehydroquinate synthase	drug development	potential antibiotic target	
4.2.3.4	3-dehydroquinate synthase	drug development	potential target for new antimicrobial agents, anti-parasitic agents and herbicides	
1.13.11.6	3-hydroxyanthranilate 3,4-dioxygenase	drug development	the enzyme is a a potential target in treating numerous disorders related to the concentration of quinolinic acid, the kynurenine pathway product	
1.13.11.6	3-hydroxyanthranilate 3,4-dioxygenase	drug development	the enzyme is a target for pharmacological downregulation because it is involved in formation of quinolinic acid, a highly potent excitotoxin implicated in a number of neurodegenerative conditions	
1.14.15.30	3-ketosteroid 9alpha-monooxygenase	drug development	the enzyme can be a target for inhibition in treatment of tuberculosis	
1.1.1.100	3-oxoacyl-[acyl-carrier-protein] reductase	drug development	the enzyme has no isoforms and thus is a good target for inhibitor design	
1.1.1.100	3-oxoacyl-[acyl-carrier-protein] reductase	drug development	FabG is the antibacteria target of maple leaf extracts and tannic acid, and both reversible and irreversible inhibitions of FabG are important for the antibacterial effect	
1.1.1.100	3-oxoacyl-[acyl-carrier-protein] reductase	drug development	galangal extract inhibits FabG, thereby displaying antibacterial ability	
2.5.1.19	3-phosphoshikimate 1-carboxyvinyltransferase	drug development	differential inhibition of class I and class II EPSPS by tetrahedral reaction intermediate-analogues possibly due to alteration of open-close transition during catalysis and/or upon inhibitor binding but not due to energy differences during complex formation	
2.5.1.19	3-phosphoshikimate 1-carboxyvinyltransferase	drug development	more experimental data needed for effective structure-based drug design	
2.5.1.19	3-phosphoshikimate 1-carboxyvinyltransferase	drug development	protonated enolpyruvylshikimate 3-phosphate (cation) intermediate as potential target for inhibitor design	
1.1.1.357	3alpha-hydroxysteroid 3-dehydrogenase	drug development	testosterone is converted to 5alpha-dihydrotestosterone, which is present at high concentrations in patients with castration resistant prostate cancer (CRPC). Inhibition of 17beta-HSD5 is therefore considered to be a promising therapy for treating CRPC. High-throughput inhibitor screening, overview	
1.1.1.213	3alpha-hydroxysteroid 3-dehydrogenase (Re-specific)	drug development	the enzyme is a target for treatment of chronic pain in neuropathic diseases, overview	
1.1.1.213	3alpha-hydroxysteroid 3-dehydrogenase (Re-specific)	drug development	2'-hydroxyflavanone may be useful for clinical therapy of malignancies where AKR1C3 is overexpressed like in prostate and breast cancer	
1.1.1.50	3alpha-hydroxysteroid 3-dehydrogenase (Si-specific)	drug development	the enzyme is a target for treatment of chronic pain in neuropathic diseases, overview	
1.3.8.2	4,4'-diapophytoene desaturase (4,4'-diapolycopene-forming)	drug development	the enzyme CrtN is an attractive and druggable target for fighting pigmented Staphylococcus aureus infections	
2.7.1.148	4-(cytidine 5'-diphospho)-2-C-methyl-D-erythritol kinase	drug development	enzyme is a target for antimicrobial drug development	
2.7.1.148	4-(cytidine 5'-diphospho)-2-C-methyl-D-erythritol kinase	drug development	potential target for anti-infective drugs	
2.7.1.148	4-(cytidine 5'-diphospho)-2-C-methyl-D-erythritol kinase	drug development	enzymes of the MEP pathway represent potential targets for the generation of selective antibacterial, antimalarial and herbicidal molecules	
6.2.1.12	4-coumarate-CoA ligase	drug development	the enzyme is a target for developing effective plant growth inhibitors, overview	
2.4.1.152	4-galactosyl-N-acetylglucosaminide 3-alpha-L-fucosyltransferase	drug development	development of a high-throughput screening system for identification of FucT-VII inhibitors, which could have anti-inflammatory or anti-metastatic potential, utilizing scintillation proximity assay with fetuin-coated beads, overview	
2.4.1.152	4-galactosyl-N-acetylglucosaminide 3-alpha-L-fucosyltransferase	drug development	fucosyltransferase VII is a very promising drug target for treatment of inflammatory skin diseases	
2.4.1.152	4-galactosyl-N-acetylglucosaminide 3-alpha-L-fucosyltransferase	drug development	FucT-VII and the E- and P-selectin pathways may prove a fruitful therapeutic target in the prevention or treatment of atherosclerosis	
1.17.1.8	4-hydroxy-tetrahydrodipicolinate reductase	drug development	enzyme is a potential target for new antimicrobial and herbicidal compounds	
4.3.3.7	4-hydroxy-tetrahydrodipicolinate synthase	drug development	DHDPS is a potential antibiotic target	
4.3.3.7	4-hydroxy-tetrahydrodipicolinate synthase	drug development	the allosteric binding site of DHDPS may be a good starting point for development of an inhibitor specific to Neisseria meningitidis	
4.3.3.7	4-hydroxy-tetrahydrodipicolinate synthase	drug development	the intracellular enzyme dihydrodipicolinate synthase a potential drug target because it is essential for the growth of bacteria while it is absent in humans	
4.3.3.7	4-hydroxy-tetrahydrodipicolinate synthase	drug development	the enzyme is a bona fide drug target for treatment of the Crown Gall disease on crops caused by Agrobacterium tumefaciens, rational design of pesticide agents	
4.3.3.7	4-hydroxy-tetrahydrodipicolinate synthase	drug development	the enzyme is an attractive target for rational antibiotic and herbicide design	
4.3.3.7	4-hydroxy-tetrahydrodipicolinate synthase	drug development	the enzyme is an attractive target for the design and synthesis of herbicides and antibiotics	
4.3.3.7	4-hydroxy-tetrahydrodipicolinate synthase	drug development	the enzyme is a promising antibiotic target	
4.3.3.7	4-hydroxy-tetrahydrodipicolinate synthase	drug development	the enzyme is a target for antibiotics	
4.3.3.7	4-hydroxy-tetrahydrodipicolinate synthase	drug development	the enzyme is an anti-cholera target	
1.14.13.2	4-hydroxybenzoate 3-monooxygenase	drug development	p-hydroxybenzoate hydroxylase (PobA) from Pseudomonas putida is a possible drug target to combat tetracycline resistance, in complex with flavin adenine dinucleotide (FAD)	
1.13.11.27	4-hydroxyphenylpyruvate dioxygenase	drug development	4-hydroxyphenylpyruvate dioxygenase (HPPD), an essential enzyme in tyrosine catabolism, is an important target for treating type I tyrosinemia	
1.13.11.27	4-hydroxyphenylpyruvate dioxygenase	drug development	4-hydroxyphenylpyruvate dioxygenase is one of the most promising target sites for herbicide discovery	
1.13.11.27	4-hydroxyphenylpyruvate dioxygenase	drug development	plant 4-hydroxyphenylpyruvate dioxygenase (HPPD) is the molecular target for development of specific inhibitors	
1.13.11.27	4-hydroxyphenylpyruvate dioxygenase	drug development	the enzyme is a target for inhibitor and herbicide development